As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012 | GenomeWeb

By Monica Heger

This story was originally published March 9.

Strong sales of Sequenom's sequencing-based MaterniT21 test to diagnose fetal aneuploidies helped the company more than double its fourth-quarter diagnostic revenue to $2.8 million from $1.2 million in the same period of 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.